KalVista Pharmaceuticals, Inc.
KALV
$13.55
-$0.05-0.37%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -44.08% | -12.99% | 37.85% | 5.42% | 12.26% |
| Gross Profit | 44.08% | 12.99% | -37.85% | -5.42% | -12.26% |
| SG&A Expenses | 185.53% | 174.01% | 79.86% | 198.41% | 54.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.53% | 54.01% | 51.98% | 52.72% | 23.03% |
| Operating Income | -29.53% | -54.01% | -51.98% | -52.72% | -23.03% |
| Income Before Tax | -52.48% | -52.87% | -59.75% | -69.74% | -36.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.11% | -52.87% | -59.75% | -69.74% | -36.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.11% | -52.87% | -59.75% | -69.74% | -36.26% |
| EBIT | -29.53% | -54.01% | -51.98% | -52.72% | -23.03% |
| EBITDA | -29.65% | -54.27% | -52.22% | -52.94% | -23.17% |
| EPS Basic | -10.23% | -13.16% | -18.91% | -33.72% | -10.98% |
| Normalized Basic EPS | -0.32% | -12.47% | -18.37% | -34.60% | -11.81% |
| EPS Diluted | -10.23% | -13.16% | -18.91% | -33.72% | -10.98% |
| Normalized Diluted EPS | -0.32% | -12.47% | -18.37% | -34.60% | -11.81% |
| Average Basic Shares Outstanding | 51.59% | 35.09% | 34.34% | 26.93% | 22.79% |
| Average Diluted Shares Outstanding | 51.59% | 35.09% | 34.34% | 26.93% | 22.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |